The bull market is roaring higher, and many growth stocks have led the gains -- but this doesn't mean your opportunity to buy growth stocks for a good price is over. Plenty of players with great long-term prospects haven't yet benefited from this favorable market environment, and instead have remained ...
motleyfoolusx:mrnausx:ntla
According to some new data revealed by Moderna (NASDAQ: MRNA) at the American Association for Cancer Research Annual Meeting on April 8, the biotech responsible for the Spikevax coronavirus vaccine may have another blockbuster drug in the works, this time a personalized cancer vaccine (PCV) for head ...
motleyfoolusx:mrnausx:mrk
For many, Moderna (NASDAQ: MRNA) stock is yesterday's news. The stock earned a great deal of attention during the coronavirus pandemic, as it was one of the early developers of a vaccine to fight off the global health scourge. Since then, it's been a bit of an off-radar stock, largely because it hasn't ...
motleyfoolusx:mrna
No pair of companies dominated the COVID-19 vaccine market quite like Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA). Both saw their revenue and earnings skyrocket, along with their share prices, as governments rushed to buy millions of doses of their respective vaccines. However, this tailwind came to ...
motleyfoolusx:mrnausx:pfe
Before the COVID-19 pandemic, most investors likely hadn't heard of Moderna (NASDAQ: MRNA). At the end of 2019, it was a relatively small biotech company with only collaboration and grant revenue and no commercially available products. What followed was a wild ride in which Moderna burst into the public ...
motleyfoolusx:mrna
It's always possible to come up with a justification for why someone should sell their shares of a stock, but that doesn't make every justification correct. For a company like Moderna (NASDAQ: MRNA) that just reported some not-so-great news, rushing to quit your position could be a mistake that causes ...
motleyfoolusx:mrna
